FATE THERAPEUTICS INC (FATE) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2019-09-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2019-09-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2019-09-30..
Borrowing debt
Overview →Financial period ending 2019-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2019-09-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2019-09-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2019-09-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 13.93M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 340.21M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2019-09-30 | (m) | (m) | $13.93M | (m) | (m) | (m) | $340.21M | (m) |
| 2019-06-30 | (m) | (m) | $5.45M | $9.47M | (m) | (m) | $199.88M | (m) |
| 2019-03-31 | (m) | (m) | $3.94M | $10.96M | (m) | (m) | $220.87M | (m) |
| 2018-12-31 | (m) | (m) | $2.44M | $12.45M | (m) | (m) | $213.03M | (m) |
| 2018-09-30 | (m) | (m) | $3.26M | $11.60M | (m) | (m) | $219.95M | (m) |
| 2018-06-30 | (m) | (m) | $2.01M | $12.84M | (m) | (m) | $83.16M | (m) |
| 2018-03-31 | (m) | (m) | $758.00K | $14.07M | (m) | (m) | $93.42M | (m) |
| 2017-12-31 | (m) | (m) | (m) | $14.81M | (m) | (m) | $105.29M | (m) |
| 2017-09-30 | (m) | (m) | (m) | $14.79M | (m) | (m) | $72.67M | (m) |
| 2017-06-30 | (m) | (m) | (m) | $6.68M | (m) | (m) | $73.95M | (m) |
| 2017-03-31 | (m) | (m) | $7.62M | $1.08M | (m) | (m) | $85.33M | (m) |
| 2016-12-31 | (m) | (m) | $8.19M | $2.50M | (m) | (m) | $95.05M | (m) |
| 2016-09-30 | (m) | (m) | $8.03M | $4.61M | (m) | (m) | $49.30M | (m) |
| 2016-06-30 | (m) | (m) | $7.86M | $6.68M | (m) | (m) | $49.18M | (m) |
| 2016-03-31 | (m) | (m) | $7.71M | $8.70M | (m) | (m) | $58.70M | (m) |
| 2015-12-31 | (m) | (m) | $7.55M | $10.69M | (m) | (m) | $67.96M | (m) |
| 2015-09-30 | (m) | (m) | $6.49M | $12.63M | (m) | (m) | $76.40M | (m) |
| 2015-06-30 | (m) | (m) | $5.16M | $14.54M | (m) | (m) | $83.48M | (m) |
| 2015-03-31 | (m) | (m) | $3.26M | $16.41M | (m) | (m) | $44.49M | (m) |
| 2014-12-31 | (m) | (m) | $1.55M | $18.08M | (m) | (m) | $51.20M | (m) |
| 2014-09-30 | (m) | (m) | $611.00K | $9.39M | (m) | (m) | $47.01M | (m) |
| 2014-06-30 | (m) | (m) | $746.00K | (m) | (m) | (m) | $43.55M | (m) |
| 2014-03-31 | (m) | (m) | $1.24M | (m) | (m) | (m) | $49.65M | (m) |
| 2013-12-31 | (m) | (m) | $1.73M | (m) | (m) | (m) | $55.58M | (m) |
| 2013-09-30 | (m) | (m) | $1.97M | $250.00K | (m) | (m) | $23.04M | (m) |
| 2012-12-31 | (m) | (m) | $1.94M | $1.73M | (m) | (m) | $11.08M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |